The first medicinal products used to treat oncologic diseases and ATMPs will be assessed within the framework of the Joint Clinical Assessments on the level of the European Union (EU) starting in 2025. Until then, the necessary health technology assessment (HTA) process needs to be defined and refined.

Today, we were honored to present our findings on the challenges and chances of the EU-HTA to the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). We analyzed the schedules and timelines of the EU-HTA according to the current plan and highlighted important considerations to take when setting up a system for a uniform HTA within the EU.

We’re happy to share our presentation with you. Please find more information in the file below. Feel free to contact us in case you have any further questions!

WS Value & Dossier – Challenges and Chances of the EU-HTA